India's nutraceutical market to hit $55–57 billion by 2030, CareEdge report
Synopsis
India's nutraceutical sector is set to nearly double in six years — from $29–30 billion today to $55–57 billion by 2030. A CareEdge Ratings report frames this as a structural shift, not a trend: post-pandemic demand, FMCG consolidation, and government policy are converging to turn supplements from a niche category into a mainstream healthcare pillar.
Key Takeaways
India's nutraceutical market was valued at $29–30 billion in 2024 and is projected to reach $55–57 billion by 2030 .
Growth is forecast at a CAGR of approximately 10.5% , with an interim target of $37–38 billion by 2026 .
The COVID-19 pandemic accelerated the shift from niche wellness to mainstream dietary support, spurring FMCG acquisitions of mid-sized brands.
FSSAI and MoFPI are strengthening regulatory frameworks, compliance, and food safety standards for the sector.
Key challenges include misleading product claims, consumer awareness gaps, and limited scientific validation for certain products.
India's nutraceutical market, currently valued at $29–30 billion, is on course to nearly double to $55–57 billion by 2030, growing at a compound annual growth rate (CAGR) of approximately 10.5%, according to a report released on Friday, 26 June by CareEdge Ratings. An interim milestone of $37–38 billion is projected by 2026, underscoring the sector's sustained upward trajectory.
Key Growth Drivers
The expansion is being propelled by rising health consciousness among Indian consumers, higher disposable incomes, and a sharp increase in lifestyle-related disorders such as diabetes and obesity. Demand for natural, science-backed nutrition products has accelerated this shift.
The proliferation of digital platforms and e-commerce has broadened market access, particularly in Tier-2 and Tier-3 cities. India's strong bio-agricultural base — with its diverse crop portfolio — also provides a structural advantage in raw material sourcing, reducing import dependence for manufacturers.
Post-Pandemic Structural Shift
The COVID-19 pandemic marked a structural turning point for the sector, according to the CareEdge Ratings report. Nutraceuticals moved from niche wellness products to everyday dietary essentials, prompting larger FMCG companies to acquire mid-sized brands and consolidate the market. The Indian healthcare landscape, the report noted, has broadly shifted from illness treatment toward prevention, wellness, and long-term health management.
Government and Regulatory Support
Supportive government policy has been a key enabler. The Food Safety and Standards Authority of India (FSSAI) and the Ministry of Food Processing Industries (MoFPI) have introduced initiatives to tighten compliance, promote food safety, and encourage innovation in functional foods and dietary supplements. Improved regulatory frameworks and standardisation measures are helping formalise what was previously a fragmented sector.
Challenges Ahead
Despite robust growth prospects, the industry faces headwinds. The CareEdge Ratings report flags evolving regulatory frameworks, consumer awareness gaps, misleading product claims, and limited scientific validation for certain products as persistent concerns that could undermine long-term credibility.
Uday Kumar, lead analyst at CareEdge Ratings, said: 'The Indian nutraceutical industry is set for sustained long-term growth, driven by rising health awareness, persistent malnutrition, supportive government policies, increasing adoption of preventive healthcare, and evolving lifestyle trends.' As regulatory clarity improves and scientific validation becomes standard, the sector's next phase of growth is expected to be both broader and more resilient.
Point of View
But the nutraceutical sector's credibility problem is just as striking — misleading claims and weak scientific validation remain unresolved. The real test for regulators is whether FSSAI can enforce standards fast enough to match market growth, or whether a wave of under-validated products erodes consumer trust before the $55 billion milestone arrives. FMCG consolidation is a double-edged signal: it validates the category, but large incumbents have historically prioritised marketing over clinical rigour. India's persistent malnutrition burden gives nutraceuticals genuine public-health relevance — but only if the regulatory floor rises in step with the market ceiling.
NationPress
26 Jun 2026
Frequently Asked Questions
What is the projected size of India's nutraceutical market by 2030?
India's nutraceutical market is projected to reach $55–57 billion by 2030, up from $29–30 billion in 2024, according to a CareEdge Ratings report. This represents a near-doubling over six years at a CAGR of approximately 10.5%.
What is driving growth in India's nutraceutical sector?
Growth is driven by rising health consciousness, higher disposable incomes, increasing lifestyle-related disorders, and demand for natural, science-backed nutrition. The expansion of e-commerce, supportive government policy, and India's strong bio-agricultural base are additional enablers.
How did the COVID-19 pandemic affect India's nutraceutical industry?
The pandemic was a structural turning point, shifting nutraceuticals from niche wellness products to everyday dietary essentials. It also prompted larger FMCG companies to acquire mid-sized nutraceutical brands, accelerating market consolidation.
What role are FSSAI and MoFPI playing in the nutraceutical sector?
The Food Safety and Standards Authority of India (FSSAI) and the Ministry of Food Processing Industries (MoFPI) have introduced initiatives to tighten compliance, promote food safety, and encourage innovation in functional foods and dietary supplements. Their efforts are helping formalise and standardise a previously fragmented sector.
What challenges does India's nutraceutical industry face?
The industry faces evolving regulatory frameworks, consumer awareness gaps, misleading product claims, and limited scientific validation for certain products, according to the CareEdge Ratings report. These challenges could undermine long-term sector credibility if left unaddressed.
